Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEATcc phase III trial in metastatic, persistent, or recurrent cervical cancer
2024-514179-17-00Phase 3Completed
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
- Start
- Oct 2018
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of atezolizumab, bevacizumab and paclitaxel in Cervical Cancer (CC) (2 arms), sponsored by Grupo Español de Investigación en Cáncer de Ovario. Primary endpoints: Progression-free survival and Overall survival. Started Oct 2018; status: completed.
02
Drugs
atezolizumabbevacizumabpaclitaxel
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2024-514179-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514179-17-00.